We are live on ! Find out more
VIVO

Meridian Bioscience Inc

Delisted

VIVO was delisted on the 30th of January, 2023.

159 hedge funds and large institutions have $723M invested in Meridian Bioscience Inc in 2015 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 64 increasing their positions, 41 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

56% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 41

17% more capital invested

Capital invested by funds: $621M → $723M (+$102M)

10% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 20

5% more call options, than puts

Call options by funds: $1.48M | Put options by funds: $1.41M

1% less funds holding

Funds holding: 160159 (-1)

Holders
159
Holders Change
-1
Holders Change %
-0.63%
% of All Funds
4.24%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
22
Increased
64
Reduced
41
Closed
20
Calls
$1.48M
Puts
$1.41M
Net Calls
+$67K
Net Calls Change
+$1.09M
Name Holding Trade Value Shares
Change
Change in
Stake
JMPWA
126
JP Morgan Private Wealth Advisors
California
$213K
PI
127
PineBridge Investments
New York
$207K +$29.3K +1,583 +17%
BC
128
Bartlett & Co
Ohio
$170K
MERSOM
129
Municipal Employees' Retirement System of Michigan
Michigan
$149K -$51.8K -2,800 -26%
First Manhattan
130
First Manhattan
New York
$133K
Creative Planning
131
Creative Planning
Kansas
$130K
Canada Life
132
Canada Life
Manitoba, Canada
$116K
Legal & General Group
133
Legal & General Group
United Kingdom
$114K
MSA
134
Mason Street Advisors
Wisconsin
$106K +$3.35K +181 +3%
OA
135
OFI Advisors
Pennsylvania
$103K -$3.64K -197 -4%
MAA
136
Managed Account Advisors
New Jersey
$66K -$1.3M -70,272 -95%
TRCT
137
Tower Research Capital (TRC)
New York
$64K +$45.2K +2,446 +266%
US Bancorp
138
US Bancorp
Minnesota
$54K +$9.25K +500 +21%
Citigroup
139
Citigroup
New York
$43K +$7.54K +408 +22%
LFR
140
Lehman Financial Resources
Pennsylvania
$38K
PCM
141
Prelude Capital Management
New York
$36K -$3.7K -200 -10%
KBC Group
142
KBC Group
Belgium
$30K
HF
143
Hoxton Financial
West Virginia
$29K
LTFS
144
Ladenburg Thalmann Financial Services
Florida
$29K +$2.26K +122 +9%
Barclays
145
Barclays
United Kingdom
$24K -$68.3K -3,693 -75%
BlackRock
146
BlackRock
New York
$24K
Teacher Retirement System of Texas
147
Teacher Retirement System of Texas
Texas
$24K +$462 +25 +2%
Bank of Montreal
148
Bank of Montreal
Ontario, Canada
$23K +$2.26K +122 +11%
GT
149
Glenmede Trust
Pennsylvania
$22K -$22.8K -1,231 -51%
BAM
150
Bruderman Asset Management
New York
$21K +$20.3K +1,098 New

VIVO Hedge Fund Activity: Q1 2015 in Review

159 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Meridian Bioscience Inc (VIVO) for Q1 2015, worth a combined $723M — up 17% from $621M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new VIVO positions and 20 closed out — a net gain of 2 holders — while 64 added to existing stakes and 41 trimmed.

The largest buyer was Schroder Investment Management Group, adding an estimated $17.2M. The largest seller was Fidelity Investments, cutting an estimated $24.6M.

  • 159 institutional investors held Meridian Bioscience Inc (VIVO) as of Q1 2015, down from 160 in Q4 2014.
  • Funds reported $723M of Meridian Bioscience Inc stock for Q1 2015, up 17% quarter-over-quarter.
  • 22 funds opened new Meridian Bioscience Inc positions in Q1 2015 and 20 closed out, a net change of +2 holders.
  • The largest Meridian Bioscience Inc buyer in Q1 2015 was Schroder Investment Management Group, an estimated $17.2M added.
  • The largest Meridian Bioscience Inc seller in Q1 2015 was Fidelity Investments, an estimated $24.6M sold.

Based on aggregated 13F filings for Q1 2015.